AFFiRiS appoints Ali Alloueche CBO
This article was originally published in Scrip
AFFiRiS, an Austrian firm developing tailor-made peptide vaccines for Alzheimer's disease, atherosclerosis, Parkinson's disease and hypertension among others, has recruited Ali Alloueche chief business officer. Mr Alloueche most recently served as head of external R&D at GlaxoSmithKline Biologics, and also has past experience at Novartis.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.